Cargando…

Nonclinical safety assessment of repeated administration and biodistribution of ChAd3‐EBO‐Z Ebola candidate vaccine

ChAd3‐EBO‐Z is an investigational adenovirus‐based vaccine for the prevention of Ebola virus disease. Two nonclinical studies were performed to evaluate the biodistribution, local tolerance and potential local and systemic toxic effects of this vaccine. In the biodistribution study, rats received a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Planty, Camille, Chevalier, Guillaume, Duclos, Marie‐Ève, Chalmey, Clémentine, Thirion‐Delalande, Catherine, Sobry, Cécile, Steff, Ann‐Muriel, Destexhe, Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318182/ https://www.ncbi.nlm.nih.gov/pubmed/31965598 http://dx.doi.org/10.1002/jat.3941

Ejemplares similares

ChAd155-RSV vaccine is immunogenic and efficacious against bovine RSV infection-induced disease in young calves
por: de Jong, Rineke, et al.
Publicado: (2022)

Humoral immunogenicity and tolerability of heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 vaccination in hemodialysis patients: A multicenter prospective observational study
por: Haase, Michael, et al.
Publicado: (2022)

EBO accredited first centre in Romania
por: Mihail, Zemba
Publicado: (2018)

Depressive symptoms among survivors of Ebola virus disease in Conakry (Guinea): preliminary results of the PostEboGui cohort
por: Keita, Mamady Mory, et al.
Publicado: (2017)

Immunogenicity of ChAd63 + MVA ME-TRAP in Senegalese adults
por: Mensah, Victorine, et al.
Publicado: (2014)

Taxonomic revision of the threatened African genus Pseudohydrosme Engl. (Araceae), with P. ebo, a new, critically endangered species from Ebo, Cameroon
por: Cheek, Martin, et al.
Publicado: (2021)

Comparative analysis of the oral mucosae from rodents and non-rodents: Application to the nonclinical evaluation of sublingual immunotherapy products
por: Thirion-Delalande, Catherine, et al.
Publicado: (2017)

Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial
por: Tapia, Milagritos D, et al.
Publicado: (2016)

Biodistribution of intravitreal (lenadogene) nolparvovec gene therapy in nonhuman primates
por: Calkins, David J., et al.
Publicado: (2021)

Humoral immunogenicity of ChAd63_MVA ME-TRAP vaccination in African infants and children
por: Bowyer, Georgina, et al.
Publicado: (2014)

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants
por: Afolabi, Muhammed O, et al.
Publicado: (2016)

Nonclinical pharmacokinetics and biodistribution of VSV-GP using methods to decouple input drug disposition and viral replication
por: Dambra, Richard, et al.
Publicado: (2022)

Understanding Long-term Evolution and Predictors of Sequelae of Ebola Virus Disease Survivors in Guinea: A 48-Month Prospective, Longitudinal Cohort Study (PostEboGui)
por: Diallo, Mamadou Saliou Kalifa, et al.
Publicado: (2021)

Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector
por: O’Hara, Geraldine A., et al.
Publicado: (2012)

Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan
por: Younis, Brima M., et al.
Publicado: (2021)

Single-Shot ChAd3-MARV Vaccine in Modified Formulation Buffer Shows 100% Protection of NHPs
por: Finch, Courtney L., et al.
Publicado: (2022)

2064. In Vitro Susceptibility of Recent Mycobacterium abscessus Isolates to Epetraborole (EBO) and Comparators by Broth Microdilution
por: Nguyen, Minh-Vu H, et al.
Publicado: (2023)

A novel Plasmodium vivax vaccine based on recombinant chimpanzee adenovirus ChAd63 and MVA expressing TRAP
por: Bauza, Karolis, et al.
Publicado: (2012)

Nonclinical study and applicability of the absorbed dose conversion method with a single biodistribution measurement for targeted alpha-nuclide therapy
por: Sakashita, Tetsuya, et al.
Publicado: (2021)

The Widely Conserved ebo Cluster Is Involved in Precursor Transport to the Periplasm during Scytonemin Synthesis in Nostoc punctiforme
por: Klicki, Kevin, et al.
Publicado: (2018)

Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial
por: de Graaf, Hans, et al.
Publicado: (2021)

A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2
por: Hassan, Ahmed O., et al.
Publicado: (2020)

Chad : development potential and constraints /
Publicado: (1974)

Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection
por: Elias, Sean C, et al.
Publicado: (2014)

AZD1222 (ChAdOx1 nCov-19): A Single-Dose biodistribution study in mice
por: Stebbings, Richard, et al.
Publicado: (2022)

Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors
por: Sheehy, Susanne H., et al.
Publicado: (2012)

A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS
por: de Barra, Eoghan, et al.
Publicado: (2014)

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal
por: Mensah, Victorine A., et al.
Publicado: (2016)

A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH
por: Osman, Mohamed, et al.
Publicado: (2017)

Target dIsease-Guided placEbo-contRolled (TIGER) design: a novel method for clinical trials of acupuncture
por: Zheng, Wenke, et al.
Publicado: (2013)

Assessment of Humoral Immune Responses to Blood-Stage Malaria Antigens following ChAd63-MVA Immunization, Controlled Human Malaria Infection and Natural Exposure
por: Biswas, Sumi, et al.
Publicado: (2014)

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children
por: Tiono, Alfred B., et al.
Publicado: (2018)

Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP
por: Rampling, Tommy, et al.
Publicado: (2018)

Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12–23 Months of Age
por: Díez-Domingo, Javier, et al.
Publicado: (2022)

Interlaboratory comparison for the Filovirus Animal Nonclinical Group (FANG) anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay
por: Anderson, Michael S., et al.
Publicado: (2020)

Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals
por: Hodgson, Susanne H., et al.
Publicado: (2015)

Rift Valley Fever in Chad
por: Ringot, David, et al.
Publicado: (2004)

The Peculiar Epidemiology of Dracunculiasis in Chad
por: Eberhard, Mark L., et al.
Publicado: (2014)

Seroprevalence and molecular characterization of foot‐and‐mouth disease virus in Chad
por: Abdel‐Aziz, Arada Izzedine, et al.
Publicado: (2019)

Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso
por: Morter, Richard, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3818t3hee5aaa53dfcvcrnjanu